Clinical Interest of the TcPO2 Technique (CINEYSOFT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01808989|
Recruitment Status : Recruiting
First Posted : March 12, 2013
Last Update Posted : June 14, 2018
The measurement of the transcutaneous oxygen pressure records simultaneously the tcpO2 at the buttocks and chest level during walking. Before and after exercise the diagnosis, investigations and treatments ongoing or to be performed are recorded.
The present study focuses on the clinical interest of the transcutaneous oxygen pressure during exercise in the diagnosis of claudication in patient referred for an oximetry exercise test.
|Condition or disease||Intervention/treatment|
|Claudication||Other: Exercise oxymetry|
Pre-test diagnostic hypothesis with probability will be completed by the physician.
Pre-test and post test ongoing or scheduled treatments will be completed by the physician.After the test, the same post test items will be evaluated.
Analysis will be done on differences of pre and post test results.
|Study Type :||Observational|
|Estimated Enrollment :||3500 participants|
|Official Title:||Multicentric Study of the Clinical Interest of the TcPO2 Technique|
|Actual Study Start Date :||November 2013|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||May 2020|
- The percentage of patients for whom results tcpO2 effort led to changes in diagnosis measured by the questionnaire filled by the doctor in charge of the patient before and after the test [ Time Frame: up to 1 day ]during a walk on a treadmill, there is a DROP of tcpo2<-15
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01808989
|Contact: Pierre ABRAHAM, MD; Ph.D||33-(0)-2-41-35-36-10||PiAbraham@chu-angers.fr|
|Contact: Isabelle DURAND ZALESKI, MD; Ph.D||33-(0)-email@example.com|
|Angers, France, 49933|
|Contact: Pierre ABRAHAM, MD, Ph.D 33-(0)-2-41--35-36-10 PiAbraham@chu-angers.fr|
|Contact: Isabelle DURAND ZALESKI, MD, Ph.D 33-(0)-40-27-41-43 firstname.lastname@example.org|
|Principal Investigator: Pierre ABRAHAM, MD, Ph.D|
|Sub-Investigator: Isabelle DURAND ZALESKI, MD, Ph.D|
|Contact: Christophe LAMOTTE, MD|
|Sub-Investigator: Christophe LAMOTTE|
|Contact: Jacques CHEVALIER|
|Sub-Investigator: Jacques CHEVALIER|
|Sub-Investigator: Remi LAURENT|
|Contact: Gabrielle SARLON|
|Sub-Investigator: Gabrielle SARLON, MD|
|Contact: Marc Antoine PISTORIUS|
|Sub-Investigator: Marc Antoine PISTORIUS|
|Sub-Investigator: Nicolas BREBION|
|Contact: Guillaume MAHE, MD|
|Sub-Investigator: Guillaume MAHE, MD|
|Contact: Alessandra Bura Riviere, MD PhD|
|Sub-Investigator: Alessandra BURA RIVIERE, MD PhD|
|Contact: Marion Aubourg, MD|
|Sub-Investigator: Marion Aubourg, MD|
|Principal Investigator:||Pierre Abraham, MD; PhD||University hospital, Angers, FRANCE|